ASH 2022 | Analysis from MOST: disease progression and leukemic transformation in lower-risk myelofibrosis
In this video, Rami Komrokji, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, shares some insights into an analysis of the MOST trial (NCT02953704), which evaluated disease progression and leukemic transformation (LT) in patients with lower-risk myelofibrosis (MF). Dr Komrokji highlights the number of patients that had physician-reported progressive disease (PD) and LT, and factors influencing these, including changes in hematological parameters and spleen size. Future analyses will focus on molecular post-baseline data, which may help elucidate the risk factors for disease progression. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
CTI BioPharma, Innovent: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Servier: Consultancy, Honoraria, Speakers Bureau; Taiho Oncology: Consultancy, Membership on an entity’s Board of Directors or advisory committees; PharmaEssentia, Takeda: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Geron: Consultancy; Acceleron Pharma: Consultancy; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; AbbVie: Consultancy, Honoraria, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Honoraria, Speakers Bureau; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau.
